L 377202Alternative Names: Doxorubicin peptide conjugate - Merck
Latest Information Update: 29 Jan 2008
At a glance
- Originator Merck & Co
- Class Anthracyclines; Cytostatic antibiotics
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer